Our science

Throughout 13 years of Selvita operations, we’ve had the opportunity to execute a variety of exciting and complex projects for our Clients.
The nature of our business is based on high degree of trust and confidentiality, however we are always very excited to co-author or contribute to scientific publications which present our work.

Whenever possible we publish and present materials such as journal publications, posters, case studies or technical notes, aiming to show the scope of experience of our scientific team.
In the section below, you can find the continuously updated information on our recent publications.

Our science

Blog

05 November 2020

Precision medicine and synthetic lethality in cancer studies at Selvita

 Continue reading
15 September 2020

Deuteration: a way to put an old drug in the spotlight again

 Continue reading
13 August 2020

Chemistry under high pressure: a curiosity or a practical solution?

 Continue reading
16 July 2020

COVID-19, a new battleground for drug discovery

 Continue reading
Go to blog

Case studies

16 July 2020

Case Study 02 (from H2L to Clinical Trials)

 Continue reading
13 July 2020

Case Study 01 (Screen-to-Lead)

 Continue reading
More case studies

Presentations

Go to presentations

Poster presentations

Poster icon
26 August 2020 LC/HRMS ORBITRAP Technique - Essential tool in drug development process
Download presentation

    The download link has been sent to the e-mail address.
    Poster icon
    07 July 2020 Cloning and Expression Platform for Production of Recombinant Proteins
    The poster describes the cost and time-effective Selvita platform for cloning and E. coli expression (which is only one of our platforms for expression).
    Download presentation

      The download link has been sent to the e-mail address.
      Poster icon
      07 July 2020 A short synthesis of Dronedarone
      Selvita’s chemists are adept at designing enhanced approaches to target molecules and in this poster and paper illustrate how they collaborated on a synthesis of the atrial fibrillation drug Dronedrone which has been reworked to more than half the number of synthetic steps using efficient and environmentally friendly chemistry.
      Download presentation

        The download link has been sent to the e-mail address.
        Go to poster presentations

        Publications

        Poster icon
        Mitogenic activity and proliferative effect of a New-developed short acting Insulin analogue Human insulin analogues with modified amino acid sequence may exert stronger proliferative effect and carcinogenic potential than insulin itself. The objective of the study was to assess mitogenic activity and activation of proliferation in tumorigenic and non-tumorigenic cell lines upon stimulation with a new-developed short-acting B28Lys-B29Pro human insulin (KP) in comparison to EU Pharmacopeia human insulin standard (HIS) and insulin AspB10 with strong mitogenic, cancerogenic activity. Find out more
        Go to publications

        Technical notes

        Development of an in vitro assay of neurodegeneration using human pluripotent stem cell–derived neurons

        Human induced pluripotent stem cells (hiPSC) are obtained by genetically reprogramming somatic cells from human tissues, after which these cells can be further differentiated virtually into any cell types. hiPSC are derived from normal adults or from diseased patients and carry protein mutations that are able to compromise the cell physiology.

        As consequence, hiPSC-derived cells reveal a high potential for studying pathophysiological processes in basically all pathological areas including CNS, PNS, peripheral tissues (cardiac, hepatic, pulmonary, muscular, vessel, blood, etc.)…

         Find out more
        Go to technical notes

        Contact form

          According to the Regulation 2016/679 of the European Parliament and the Council (EU) of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation; "GDPR"), we hereby inform you that Your personal data will be processed by Selvita S.A. and the companies operating within the Selvita Capital Group in order to present You the Selvita Newsletter. Your personal data are processed in connection with Newsletter subscription and in order to keep You informed about all events taking place in Selvita Capital Group.

          We guarantee full transparency of the data processing and compliance with all the rights referred to in GDPR, i.e. the right of access, rectification and deletion of data, limiting data processing, the right to transfer, the right to raise objection against processing. Notwithstanding the above, You have the right to submit a complaint to the supervisory authority. Your personal data are not being subject to automated decision-making, including profiling. Your personal data are provided on the voluntary basis, however please be informed that lack of consent results in inability to provide You the Newsletter by Selvita Group. Your data will be processed for the duration of your consent, unless your consent to the processing of your personal data is revoked. Your consent may be withdrawn at any time by sending a request to the e-mail address: gdpr@selvita.com.

          For more information on how Selvita handles personal data please visit: Privacy Policy. I hereby express my consent to the processing of my personal data by Selvita S.A. with registered office in Cracow 30-348, Bobrzyńskiego 14 and its affiliated companies in order to receive the Newsletter, information about events organized by the Selvita Capital Group and other information regarding Selvita Group activity in accordance with the Regulation 2016/679 of the European Parliament and the Council (EU) of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation).